HALO
$112.45
▲ +2.53%09/18 O 109.72 H 112.66 L 109.38 C 112.45 ▲ +2.53%
Vol 10.2M RS 92
Vol 10.2M RS 92
RS rating92
Now vs pivot (%)+41.45%
Tightening (ATR ratio)1.01×
Volume dry-up1.11×
Up/down volume, net0.23
From 52-week high0%
played out
Halozyme Therapeutics, Inc.
HALO · Biotechnology · $12.8B
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
All four are in order, fastest above slowest — every timeframe pointing the same way.
The read
The base has run 18.8 weeks and fell 23% from its ceiling at its deepest. The pivot is $79.50, and the stock closed 41.5% above that pivot. Its relative strength rating is 92.
Peers
Catalyst roadmap
- Earningstentativein 45dQuarterly earningsNov 2, 2026
Flagged by the market sweep
Nothing flagged for this company on the last market sweep.
In the news
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026GlobeNewswire Inc. · 9 days agoIs Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?Zacks Investment Research · 12 days agoAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · 2026-09-02If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth NowZacks Investment Research · 2026-09-01
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray